AI Article Synopsis
- A study investigated the oral histone deacetylase inhibitor ITF2357 in eight patients with different autoinflammatory syndromes over 90 days.
- Some patients with Schnitzler syndrome and a TRAPS patient showed partial remission, while four patients had no improvement, and HIDS patients experienced worse symptoms.
- The results suggest that ITF2357 might help a little in Schnitzler syndrome but was ineffective for HIDS patients.
Article Abstract
We explored the effects of the oral histone deacetylase (HDAC) inhibitor ITF2357 in patients with autoinflammatory syndrome. In this prospective open-label pilot study, eight patients were enrolled; one patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS), three patients with hyper-IgD and periodic fever syndrome (HIDS) and four patients with Schnitzler syndrome were closely followed during 90 d of ITF2357 treatment. Three patients with Schnitzler syndrome and one TRAPS patient experienced a partial remission. In four patients, there was no effect. In HIDS patients, there was a tendency toward a higher attack frequency and increasing attack severity. In two patients (one TRAPS and one HIDS), we observed a decrease of acute-phase response without signs of clinical improvement. One patient with Schnitzler syndrome showed a partial response despite an ongoing acute-phase response. In conclusion, ITF2357 monotherapy was able to induce partial response only in patients with Schnitzler syndrome and no response in patients with HIDS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105134 | PMC |
| http://dx.doi.org/10.2119/molmed.2011.00039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigator-initiated, multi-center, single-arm, open-label study of the effectiveness of canakinumab in Japanese patients with Schnitzler syndrome.
Allergol Int
December 2024
Department of Dermatology, Hyogo Medical University Graduate School of Medicine, Nishinomiya, Japan.
Article Synopsis
- Schnitzler syndrome is an adult-onset autoinflammatory condition presenting with a rash, fever, and fatigue, but lacks an approved treatment, prompting this study on canakinumab.
- In this phase II trial, five patients received a single dose of canakinumab, with the goal of achieving a complete clinical response (CR) and tracking improvements in quality of life and inflammatory markers.
- The results indicated that 60% of patients achieved CR by Day 7, and all patients demonstrated improvements in inflammation and quality of life, suggesting canakinumab may be beneficial for those with Schnitzler syndrome.
The population based cognitive testing in subjects with SARS-CoV-2 (POPCOV2) study: longitudinal investigation of remote cognitive and fatigue screening in PCR-positive cases and negative controls.
Front Hum Neurosci
November 2024
Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Article Synopsis
- The study examined cognitive symptoms in individuals infected with SARS-CoV-2, finding that while most had mild respiratory symptoms, many also experienced cognitive issues like attention and memory deficits.
- At baseline, those with SARS-CoV-2 showed higher fatigue levels compared to those who tested negative, but improvements in cognitive scores were noted in both groups over time.
- Ultimately, the research highlights that even mild cases of COVID-19 can be linked to increased fatigue and cognitive challenges, reinforcing previous findings.
Acquired autoinflammatory disorders: A dermatologist's perspective.
Clin Exp Dermatol
December 2024
Department of Dermatology, Venereology and Leprology; Postgraduate Institute of Medical Education and Research; Chandigarh, India.
Article Synopsis
- Autoinflammatory disorders are characterized by an exaggerated response of the innate immune system, primarily involving neutrophils and macrophages, and are differentiated from connective tissue diseases by the absence of anti-nuclear antibodies.
- Many of these disorders are linked to inherited genetic mutations and tend to manifest in childhood or early adulthood, though some, like VEXAS syndrome, highlight the potential for acquired mutations in adults.
- The review focuses on the cutaneous manifestations of various acquired autoinflammatory disorders, including adult-onset Still's disease and Schnitzler syndrome, which have significant diagnostic implications.
FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases.
Clin Exp Immunol
December 2024
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, St James' University Hospital, Leeds, United Kingdom.
Article Synopsis
- The study focuses on the detection of ASC aggregates, which are important for inflammasome assembly, particularly the NLRP3 inflammasome, after pyroptotic cell death.
- Researchers developed a method using human monocytes, macrophages, and ASC reporter cells to identify ASC/NLRP3-positive events via flow cytometry.
- Results showed increased ASC/NLRP3 specks in the sera of patients with inflammatory conditions, indicating that FACS is a reliable detection method with potential diagnostic uses in autoinflammatory diseases.
Recurrent urticaria with fever, arthralgia, and biclonal gammopathy.
JAAD Case Rep
November 2024
Department of Dermatology, Apollo Hospital, Hyderabad, Telangana, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!